As mentioned above, bevacizumab treatment is efficient in only ∼55% of patients with the wet form of age-related macular degeneration.12,13 The limited success of the VEGF targeting therapy is due partially to maturation of established vessels. The gene discussed is VEGFA; the disease is age-related macular degeneration.